FOLFIRI® and bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms
about
Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumorsInhibition of Growth and Metastasis of Tumor in Nude Mice after Intraperitoneal Injection of Bevacizumab.Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort.
P2860
FOLFIRI® and bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
FOLFIRI® and bevacizumab in fi ...... cacy and genetic polymorphisms
@ast
FOLFIRI® and bevacizumab in fi ...... cacy and genetic polymorphisms
@en
type
label
FOLFIRI® and bevacizumab in fi ...... cacy and genetic polymorphisms
@ast
FOLFIRI® and bevacizumab in fi ...... cacy and genetic polymorphisms
@en
prefLabel
FOLFIRI® and bevacizumab in fi ...... cacy and genetic polymorphisms
@ast
FOLFIRI® and bevacizumab in fi ...... cacy and genetic polymorphisms
@en
P2093
P2860
P356
P1433
P1476
FOLFIRI® and bevacizumab in fi ...... cacy and genetic polymorphisms
@en
P2093
Caroline Lalet
Dominique Béchade
Laurent Cany
Marianne Fonck
Marina Pulido
Patrick Texereau
René Brunet
Richard Beyssac
Sofiane Aitouferoukh
Valérie Le Morvan
P2860
P2888
P356
10.1186/1756-0500-7-260
P577
2014-04-23T00:00:00Z
P5875
P6179
1031900275